HC Wainwright & Co. Reiterates Buy on Liquidia, Maintains $29 Price Target
Scotiabank Maintains Liquidia(LQDA.US) With Buy Rating, Raises Target Price to $30
A Quick Look at Today's Ratings for Liquidia(LQDA.US), With a Forecast Between $19 to $31
Liquidia Technologies (LQDA) Gets a Buy From Scotiabank
Liquidia Analyst Ratings
Liquidia Technologies: Strategic Advancements and Legal Win Bolster Buy Rating
Liquidia Analyst Ratings
Scotiabank Initiates Liquidia at Sector Outperform With $30 Price Target
LifeSci Capital Maintains Liquidia(LQDA.US) With Buy Rating, Maintains Target Price $30
Raymond James Maintains Liquidia(LQDA.US) With Buy Rating
BTIG Maintains Liquidia(LQDA.US) With Buy Rating, Maintains Target Price $25
LifeSci Capital Maintains Liquidia(LQDA.US) With Buy Rating, Maintains Target Price $30
Buy Rating Affirmed for Liquidia Technologies Following Positive Legal Developments for Yutrepia
Liquidia Initiated at Outperform by LifeSci Capital
Liquidia Analyst Ratings
LifeSci Capital Initiates Liquidia(LQDA.US) With Buy Rating, Announces Target Price $30
Buy Rating for Liquidia Technologies Amidst Promising Cardiopulmonary Market Prospects
BTIG Maintains Liquidia(LQDA.US) With Buy Rating, Maintains Target Price $25
Expanding Horizons: Liquidia Technologies' Growth and Strategic Partnerships Fuel Buy Rating
H.C. Wainwright Maintains Liquidia(LQDA.US) With Buy Rating, Maintains Target Price $29